Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech stocks hitting 52-week highs on July 29)
- Acasti Pharma Inc (NASDAQ:ACST)
- Array Biopharma Inc (NASDAQ:ARRY)
- GENMAB A/S/S ADR (NASDAQ:GMAB) (IPOed July 18)
- Grifols SA - ADR ADR Class B (NASDAQ:GRFS)
- Hologic, Inc. (NASDAQ:HOLX)
- Novocure Ltd (NASDAQ:NVCR)
- Odonate Therapeutics Inc (NASDAQ:ODT)
- Repligen Corporation (NASDAQ:RGEN)
Down In The Dumps
(Biotech stocks hitting 52-week lows on July 29)
- Acer Therapeutics Inc (NASDAQ:ACER)
- Advaxis, Inc. (NASDAQ:ADXS)
- Cancer Genetics Inc (NASDAQ:CGIX)
- Champions Oncology Inc (NASDAQ:CSBR)
- China SXT Pharmaceuticals Inc (NASDAQ:SXTC)
- Genprex Inc (NASDAQ:GNPX)
- Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA)
- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)(NASDAQ:SNY)'s decision to terminate their collaboration agreement regarding sotagliflozin that is being evaluated for Type 2 diabetes)
- Myovant Sciences Ltd (NYSE:MYOV)
- Neovasc Inc (NASDAQ:NVCN)
- Neon Therapeutics Inc (NASDAQ:NTGN)
- Neuralstem, Inc. (NASDAQ:CUR)
- Novavax, Inc. (NASDAQ:NVAX)
- Oncolytics Biotech, Inc. (NASDAQ:ONCY)
- Personalis Inc (NASDAQ:PSNL)( IPOed June 20)
- Cytori Therapeutics (NASDAQ:PSTV)
- Proteostasis Therapeutics Inc (NASDAQ:PTI)
- Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)
- TRACON Pharmaceuticals Inc (NASDAQ:TCON)
- Unity Biotechnology Inc (NASDAQ:UBX)
- Vistagen Therapeutics Inc (NASDAQ:VTGN)
- Wave Life Sciences Ltd (NASDAQ:WVE) (reacted to a loss for Q2)
- Xenetic Biosciences Inc (NASDAQ:XBIO)
- Zafgen Inc (NASDAQ:ZFGN)
See Also: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate
Stocks In Focus
Coherus Wins Neulasta Biosimilar Patent Lawsuit
Coherus Biosciences Inc (NASDAQ:CHRS) said the U.S. Court of Appeals for the Federal Circuit has affirmed the decision of a U.S. district court that Coherus' Udenyca, Neulasta biosimilar, does not infringe Amgen, Inc. (NASDAQ:AMGN)'s asserted patent. Coherus launched Udenyca in the U.S. in January.
The stock gained 2.76% to $16.75 in after-hours trading.
Hepa Given Nod To Procced With IND Study Of CRV431 In NASH
Hepion Pharmaceuticals Inc (NASDAQ:HEPA), previously Contravir, said the FDA has authorized it to proceed with its planned investigational new drug application, or IND, opening study for CRV431 in non-alcoholic steatohepatitis following the review of its IND.
The company noted that the IND for NASH is in addition to the current open IND for hepatitis B virus.
The stock added 9.23% to $3.55 in after-hours trading.
Verastem Appoints Stuglik As CEO
Verastem Inc (NASDAQ:VSTM) announced the appointment of Brian Stuglik, a member of its board, as CEO. Stuglik has over three decades of experience in the pharmaceutical industry.
The stock fell 1.4% to $1.41 in after-hours trading.
Merck Combo Antibiotics Gets Backing Of European Regulatory Panel
Merck & Co., Inc. (NYSE:MRK) said the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has adopted a positive opinion recommending Zerbaxa 3g dose – a combo drug of ceftolozane and tazobactam - for an additional indication for the treatment of hospital-acquired pneumonia, including ventilator-associated pneumonia, in adults.
The stock edged up 0.25% to $82.70 in after-hours trading.
Earnings
Medpace Holdings Inc )(NASDAQ:MEDP) reported second-quarter GAAP net income of 81 cents per share compared to 61 cents reported for the year-ago period and the consensus estimate of 66 cents per share. Revenues climbed 25.8% to $214.1 million, exceeding the $202.8 million consensus estimate.
The company issued above-consensus guidance for the fiscal year 2019.
The stock rallied 9.93% to $74.40 in after-hours trading.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) reported second-quarter EPS of 54 cents, higher than the 7 cents reported last year and the 11 cents per share consensus estimate. Revenues nearly doubled to $183.58 million
The stock gained 9.81% to $91.50 in after-hours trading.
On The Radar
Earnings
Eli Lilly And Co (NYSE:LLY) (before the market open)
Iradimed Corp (NASDAQ:IRMD) (before the market open)
Blueprint Medicines Corp (NASDAQ:BPMC) (before the market open)
Meridian Bioscience, Inc. (NASDAQ:VIVO) (before the market open)
Merck & Co., Inc. (NYSE:MRK) (before the market open)
Incyte Corporation (NASDAQ:INCY) (before the market open)
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) (before the market open)
NeoGenomics, Inc. (NASDAQ:NEO) (before the market open)
Pfizer Inc. (NYSE:PFE) (before the market open)
Amgen (after the market close)
AtriCure Inc. (NASDAQ:ATRC) (after the market close)
EXACT Sciences Corporation (NASDAQ:EXAS) (after the market close)
T2 Biosystems Inc (NASDAQ:TTOO) (after the market close)
BioTelemetry Inc (NASDAQ:BEAT) (after the market close)
Gilead Sciences, Inc. (NASDAQ:GILD) (after the market close)
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) (after the market close)
Veracyte Inc. (NASDAQ:VCYT) (after the market close)
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
